ATE548350T1 - N-arylpiperidin-substituierte biphenylcarbonsäureamide als inhibitoren von apolipoprotein b - Google Patents

N-arylpiperidin-substituierte biphenylcarbonsäureamide als inhibitoren von apolipoprotein b

Info

Publication number
ATE548350T1
ATE548350T1 AT04804685T AT04804685T ATE548350T1 AT E548350 T1 ATE548350 T1 AT E548350T1 AT 04804685 T AT04804685 T AT 04804685T AT 04804685 T AT04804685 T AT 04804685T AT E548350 T1 ATE548350 T1 AT E548350T1
Authority
AT
Austria
Prior art keywords
arylpiperidine
apolipoprotein
inhibitors
carbonic acid
acid amides
Prior art date
Application number
AT04804685T
Other languages
English (en)
Inventor
Lieven Meerpoel
Marcel Viellevoye
Joannes Linders
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of ATE548350T1 publication Critical patent/ATE548350T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT04804685T 2003-12-09 2004-12-06 N-arylpiperidin-substituierte biphenylcarbonsäureamide als inhibitoren von apolipoprotein b ATE548350T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03104601 2003-12-09
PCT/EP2004/053280 WO2005058824A2 (en) 2003-12-09 2004-12-06 N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprote in b

Publications (1)

Publication Number Publication Date
ATE548350T1 true ATE548350T1 (de) 2012-03-15

Family

ID=34684566

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04804685T ATE548350T1 (de) 2003-12-09 2004-12-06 N-arylpiperidin-substituierte biphenylcarbonsäureamide als inhibitoren von apolipoprotein b

Country Status (18)

Country Link
US (1) US8772494B2 (de)
EP (1) EP1694644B1 (de)
JP (1) JP4790626B2 (de)
KR (1) KR101125120B1 (de)
CN (1) CN100548985C (de)
AT (1) ATE548350T1 (de)
AU (1) AU2004299295B2 (de)
BR (1) BRPI0417469B8 (de)
CA (1) CA2547243C (de)
EA (1) EA009081B1 (de)
ES (1) ES2383179T3 (de)
IL (1) IL176171A (de)
NO (1) NO337251B1 (de)
NZ (1) NZ546964A (de)
SG (1) SG149001A1 (de)
UA (1) UA83510C2 (de)
WO (1) WO2005058824A2 (de)
ZA (1) ZA200604718B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007053436A1 (en) * 2005-10-31 2007-05-10 Janssen Pharmaceutica N.V. Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
EP2007888A2 (de) 2006-04-03 2008-12-31 Santaris Pharma A/S Pharmazeutische zusammensetzung mit anti-mirna-antisense-oligonukleotiden
SG10201406016SA (en) 2006-04-03 2014-11-27 Stella Aps Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
US8017168B2 (en) 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
DK2149605T3 (da) 2007-03-22 2013-09-30 Santaris Pharma As Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
US8470791B2 (en) 2007-03-22 2013-06-25 Santaris Pharma A/S RNA antagonist compounds for the inhibition of Apo-B100 expression
EP2623599B1 (de) 2007-10-04 2019-01-02 Roche Innovation Center Copenhagen A/S Mikromir-Moleküle
CA2717792A1 (en) 2008-03-07 2009-09-11 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
WO2010012667A1 (en) 2008-08-01 2010-02-04 Santaris Pharma A/S Micro-rna mediated modulation of colony stimulating factors
ES2599979T3 (es) 2009-04-24 2017-02-06 Roche Innovation Center Copenhagen A/S Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
EP2456870A1 (de) 2009-07-21 2012-05-30 Santaris Pharma A/S Auf pcsk9 gerichtete antisense-oligomere
HUE048738T2 (hu) 2013-06-27 2020-08-28 Roche Innovation Ct Copenhagen As Antiszensz oligomerek és konjugátumok, amelyek a PCK9-t célozzák meg

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9826412D0 (en) * 1998-12-03 1999-01-27 Glaxo Group Ltd Chemical compounds
GB0013378D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Use of therapeutic benzamide derivatives
GB0013383D0 (en) * 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
JO2654B1 (en) * 2000-09-04 2012-06-17 شركة جانسين فارماسوتيكا ان. في Multiple aryl caroxa amides are useful as lipid - lowering agents
JO2390B1 (en) * 2001-04-06 2007-06-17 شركة جانسين فارماسوتيكا ان. في Diphenylcarboxamides act as lipid-lowering agents
GB0109287D0 (en) * 2001-04-12 2001-05-30 Glaxo Group Ltd Therapeutic benzamide derivatives
GB0129015D0 (en) 2001-12-04 2002-01-23 Glaxo Group Ltd Compounds
UA79300C2 (en) * 2002-08-12 2007-06-11 Janssen Pharmaceutica Nv N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion

Also Published As

Publication number Publication date
US20070099934A1 (en) 2007-05-03
KR20060111628A (ko) 2006-10-27
WO2005058824A2 (en) 2005-06-30
EA009081B1 (ru) 2007-10-26
NO20063103L (no) 2006-09-05
UA83510C2 (en) 2008-07-25
CA2547243A1 (en) 2005-06-30
IL176171A0 (en) 2006-10-05
WO2005058824A3 (en) 2005-10-27
SG149001A1 (en) 2009-01-29
AU2004299295A1 (en) 2005-06-30
HK1100559A1 (zh) 2007-09-21
IL176171A (en) 2013-08-29
CA2547243C (en) 2012-10-23
US8772494B2 (en) 2014-07-08
NZ546964A (en) 2009-03-31
EP1694644B1 (de) 2012-03-07
NO337251B1 (no) 2016-02-22
BRPI0417469B1 (pt) 2019-06-25
ZA200604718B (en) 2007-10-31
BRPI0417469A (pt) 2007-04-10
AU2004299295B2 (en) 2010-07-15
BRPI0417469B8 (pt) 2021-05-25
EA200601120A1 (ru) 2006-10-27
JP2007513921A (ja) 2007-05-31
JP4790626B2 (ja) 2011-10-12
KR101125120B1 (ko) 2012-03-21
CN100548985C (zh) 2009-10-14
EP1694644A2 (de) 2006-08-30
CN1890217A (zh) 2007-01-03
ES2383179T3 (es) 2012-06-18

Similar Documents

Publication Publication Date Title
DE60315336D1 (de) Pharmazeutische zusammensetzung und ihre verwendung als inhibitoren von der dipeptidyl peptidase iv (dpp-iv)
ATE419848T1 (de) Cycloalkyl-lactam-derivate als inhibitoren von 11-beta-hydroxysteroiddehydrogenase 1
EA200601660A1 (ru) Ингибирующие mtp арилпиперидины или пиперазины, замещенные 5-членными гетероциклами
SE0200920D0 (sv) Novel compounds
CY1107945T1 (el) Διφαινυλκαρβοξαμιδια υποκατεστημενα με ν-αρυλ πιπεριδινη ως αναστολεις της εκκρισης της απολιποπρωτεϊνης β
SE0301700D0 (sv) Novel compounds
GEP20074197B (en) 5ht2c receptor modulators
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
CY1109962T1 (el) Υποκατεστημενες ενωσεις 1,4,8-τριαζασπειρο[4,5]δεκαν-2-ονης για τη θεραπεια παχυσαρκιας
ATE548350T1 (de) N-arylpiperidin-substituierte biphenylcarbonsäureamide als inhibitoren von apolipoprotein b
NO20071314L (no) Peptidiske vasopressinreseptoragonister
SE0302139D0 (sv) Novel compounds
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
EA200970398A1 (ru) Производные пиперидин или пиперазин замещенной тетрагидро-нафталин 1-карбоновой кислоты, ингибирующие мтр
JO2409B1 (en) Second-phenyl carboxy amides are useful as lipid-lowering agents
JO2390B1 (en) Diphenylcarboxamides act as lipid-lowering agents
DE602004031410D1 (de) Inden derivate als pharmazeutika
SE0303280D0 (sv) Novel compounds
SE0401763D0 (sv) Compounds
SE0302755D0 (sv) Novel compounds
NO20060718L (no) Substituerte tiofoner og deres anvendelse
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
ATE308513T1 (de) Naphthamid-neurokinin antagonisten zur verwendung als medikamente
ATE461174T1 (de) Neue piperidinderivate und deren verwendung als monoaminneurotransmitter-wiederaufnahmehemmer
NO20063790L (no) Substituerte azetidin sammensetninger som cyclooxygenase-1-cyclooxygenase-2-inhibitorer, og deres fremstilling og anvendelse som medikamenter